Whilst it may not be a huge deal, we thought it was good to see that the Prelude Therapeutics Incorporated (NASDAQ:PRLD) Founder, Krishna Vaddi, recently bought US$99k worth of stock, for US$0.93 per share. Although the purchase is not a big one, increasing their shareholding by only 4.9%, it can be interpreted as a good sign.

Prelude Therapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by Krishna Vaddi is the biggest insider purchase of Prelude Therapeutics shares that we've seen in the last year. We do like to see buying, but this purchase was made at well below the current price of US$1.30. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

While Prelude Therapeutics insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Prelude Therapeutics

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 6.0% of Prelude Therapeutics shares, worth about US$4.3m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Does This Data Suggest About Prelude Therapeutics Insiders?

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Prelude Therapeutics insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Prelude Therapeutics. At Simply Wall St, we've found that Prelude Therapeutics has 5 warning signs (1 is a bit concerning!) that deserve your attention before going any further with your analysis.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.